Changzhou Qianhong Biopharma Co Ltd (002550) — Working Capital to Net Assets Ratio
Changzhou Qianhong Biopharma Co Ltd (002550) has a Working Capital to Net Assets ratio of 61.4% as of March 2026. Working capital of CN¥1.75 Billion (current assets of CN¥2.03 Billion minus current liabilities of CN¥278.06 Million) is measured against net assets of CN¥2.85 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See debt-free asset ratio of Changzhou Qianhong Biopharma Co Ltd to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Changzhou Qianhong Biopharma Co Ltd Working Capital to Net Assets (2007–2025)
This chart shows how Changzhou Qianhong Biopharma Co Ltd's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the ratio stands at 61.4%, reflecting working capital of CN¥1.75 Billion against net assets of CN¥2.85 Billion CNY. Check Changzhou Qianhong Biopharma Co Ltd (002550) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Changzhou Qianhong Biopharma Co Ltd (2007–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Changzhou Qianhong Biopharma Co Ltd from 2007 to 2025, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Changzhou Qianhong Biopharma Co Ltd market cap and net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 60.9% | CN¥1.68 Billion | CN¥2.77 Billion | CN¥1.91 Billion | CN¥224.21 Million | ▲ +2.5 pp |
| 2024 | 58.4% | CN¥1.47 Billion | CN¥2.52 Billion | CN¥1.69 Billion | CN¥223.39 Million | ▲ +1.0 pp |
| 2023 | 57.4% | CN¥1.42 Billion | CN¥2.47 Billion | CN¥1.63 Billion | CN¥205.81 Million | ▼ -0.5 pp |
| 2022 | 57.9% | CN¥1.41 Billion | CN¥2.43 Billion | CN¥1.69 Billion | CN¥278.22 Million | ▼ -2.2 pp |
| 2021 | 60.1% | CN¥1.27 Billion | CN¥2.12 Billion | CN¥1.57 Billion | CN¥296.35 Million | ▼ -1.2 pp |
| 2020 | 61.3% | CN¥1.27 Billion | CN¥2.07 Billion | CN¥1.56 Billion | CN¥290.98 Million | ▼ -5.0 pp |
| 2019 | 66.3% | CN¥1.55 Billion | CN¥2.33 Billion | CN¥2.09 Billion | CN¥541.99 Million | ▼ -5.6 pp |
| 2018 | 72.0% | CN¥1.83 Billion | CN¥2.54 Billion | CN¥2.38 Billion | CN¥554.88 Million | ▲ +1.6 pp |
| 2017 | 70.4% | CN¥1.73 Billion | CN¥2.45 Billion | CN¥2.28 Billion | CN¥555.22 Million | ▲ +16.7 pp |
| 2016 | 53.7% | CN¥1.30 Billion | CN¥2.42 Billion | CN¥1.87 Billion | CN¥572.95 Million | ▼ -19.0 pp |
| 2015 | 72.7% | CN¥1.67 Billion | CN¥2.29 Billion | CN¥2.18 Billion | CN¥508.64 Million | ▲ +4.5 pp |
| 2014 | 68.2% | CN¥1.46 Billion | CN¥2.13 Billion | CN¥1.60 Billion | CN¥143.17 Million | ▼ -4.4 pp |
| 2013 | 72.6% | CN¥1.43 Billion | CN¥1.97 Billion | CN¥1.52 Billion | CN¥88.93 Million | ▼ -19.2 pp |
| 2012 | 91.8% | CN¥1.72 Billion | CN¥1.87 Billion | CN¥1.77 Billion | CN¥51.39 Million | ▼ -2.1 pp |
| 2011 | 93.9% | CN¥1.66 Billion | CN¥1.77 Billion | CN¥1.72 Billion | CN¥57.67 Million | ▲ +7.6 pp |
| 2010 | 86.3% | CN¥357.00 Million | CN¥413.78 Million | CN¥456.27 Million | CN¥99.27 Million | ▲ +20.5 pp |
| 2009 | 65.7% | CN¥160.21 Million | CN¥243.68 Million | CN¥435.85 Million | CN¥275.63 Million | ▲ +10.7 pp |
| 2008 | 55.1% | CN¥120.04 Million | CN¥217.99 Million | CN¥293.76 Million | CN¥173.72 Million | ▲ +2.6 pp |
| 2007 | 52.5% | CN¥111.06 Million | CN¥211.61 Million | CN¥187.93 Million | CN¥76.87 Million | — |